BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent. This is a 3.29 percent decrease over sales of $304.000 thousand the same period last year.